TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03072147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
Study: NCT00707330
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged release tablet, 500 mg, 1 tablet a day for a week
Study: NCT01923909
Drug: Intra-articular corticosteroid injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
Study: NCT04817722
Drug: Intravenous Solution
Normalized name: Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative hydration
Study: NCT01916720
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT00621504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
Study: NCT00621504
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
Study: NCT00002553
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01165450
Drug: Vehicle only
Normalized name: SUSPENDING VEHICLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
Study: NCT00849797
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg Tablet
Study: NCT00849797
Drug: Trileptal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Tablet
Study: NCT01262235
Drug: TKM-080301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat dose IV infusion.
Study: NCT01748344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: None active
Study: NCT00918814
Drug: LIPO-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT00918814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01730846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03809052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard capsules for oral use
Study: NCT01950234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01872728
Drug: Bilateral facial block after general anesthesia before surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
Study: NCT01018862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
Study: NCT00664248
Drug: IDP-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application for 12 weeks
Study: NCT00664248
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application for 12 weeks
Study: NCT00664248
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application for 12 weeks
Study: NCT02708251
Drug: placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04372641
Drug: p97 Inhibitor CB-5339 Tosylate
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03622099
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
Study: NCT01777152
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Study: NCT01777152
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Study: NCT00743093
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
Study: NCT03164382
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firstly, the femoral artery was percutaneously punctured using the Seldinger technique. Then, the catheter was inserted into the celiac trunk or superior mesenteric artery for arteriography. When more than one feeding artery of HCC was detected, the smaller arteries were embolized with gelatin sponge particles. A micro-catheter was inserted through the arterial catheter located at the common hepatic artery or proper hepatic arterial branch (feeding artery). When blood flows into the gastroduodenal artery was confirmed by micro-catheter angiography, the route was embolized with a coil or micro-coil to prevent reflux of chemotherapeutic drugs to the stomach and duodenum. The peripheral part of the catheter that was exposed to the outside of the body was covered with medical sterile gauze and fastened on the thigh's skin using medical rubberized fabric and bandage. Catheter insertion was repeatedly performed before every cycle of treatment.
Study: NCT00743093
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
Study: NCT00820534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo every 2 hous during waking hours for 96 hours
Study: NCT01096329
Drug: Intrinsa® Patch and Testosterone Spray 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
Study: NCT01096329
Drug: Intrinsa® Patch and Testosterone Spray 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
Study: NCT03073850
Drug: Standard dose oral anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban of 60mg
Study: NCT01756898
Drug: 5 mg ASB17061
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.
Study: NCT01756898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo taken once daily for 28 consecutive days.
Study: NCT01756898
Drug: 10 mg ASB17061
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 10 mg ASB17061 taken once daily for 28 consecutive days.
Study: NCT01756898
Drug: 20 mg ASB17061
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 20 mg ASB17061 taken once daily for 28 consecutive days.
Study: NCT02652884
Drug: saline 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of intramuscular placebo
Study: NCT00235079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00820560
Drug: INCB007839
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB007839 100 or 200 mg/dose as IR capsules
Study: NCT01391507
Drug: COR-1
Normalized name: Corticosteroid-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravenous injection for 6 months
Study: NCT01391507
Drug: Standard therapy for heart failure
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
Study: NCT00840879
Drug: Meloxicam 15 mg Tablets
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 15 mg, single-dose fed
Study: NCT00840879
Drug: Mobic® 15 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 15 mg, single-dose fed
Study: NCT03875547
Drug: Refixia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
Study: NCT03031821
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration
Study: NCT04594252
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as tablets.
Study: NCT03197818
Drug: CHF 5993 100/6/12.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
Study: NCT00130936
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02070042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (olive oil) twice a day
Study: NCT01562548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active ingredient
Study: NCT02392286
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
Study: NCT00229021
Drug: doripenum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00834717
Drug: Kytril® 1 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 1 mg, single dose fasting
Study: NCT04183335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study: NCT04183335
Drug: Moisturizers
Normalized name: SPF 8 Lip Moisturizers KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:~Route of administration: Topical
Study: NCT04183335
Drug: Topical calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:~Route of administration: Topical
Study: NCT00352989
Drug: Smecta (Diosmectite), duration of treatment - 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01783535
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT01783535
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
Study: NCT01750294
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00665925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally, either once a day, or twice a day
Study: NCT03665194
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT04338698
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)
Study: NCT01756547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03413020
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic for H. pylori eradication
Study: NCT01171456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
Study: NCT01788007
Drug: Zyclara® (imiquimod) Topical Cream 3.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
Study: NCT01957059
Drug: Regimen Selection Phase Group 2
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg
Study: NCT01450982
Drug: JNJ-38518168 / MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
Study: NCT01243736
Drug: Combination Prep
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination bowel preparation, which consists of:~1. drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~2. drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~3. drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~4. lying on your right side for 30 minutes following the swallowing of the capsule endoscope.
Study: NCT01957059
Drug: Regimen Selection Phase Group 3
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg
Study: NCT01957059
Drug: Treatment Phase Group 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
Study: NCT01957059
Drug: Regimen Selection Phase Group 1 (COMPLETED)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses of BMN053 have been administered as subcutaneous injections.
Study: NCT01957059
Drug: Dosing Extension
Normalized name: EXTENSION TUBES
Approvals — FDA: no, EMA: no, PMDA: no
Description: All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
Study: NCT02611687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT03873805
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03220958
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml normal saline
Study: NCT01463098
Drug: E2006 1.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006 1.0 mg capsule.
Study: NCT01463098
Drug: E2006 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006 2.5 mg capsule.
Study: NCT01463098
Drug: E2006 5.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006 5.0 mg (2 capsules of 2.5 mg each).
Study: NCT01463098
Drug: E2006 10.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006 10.0 mg capsule.
Study: NCT01463098
Drug: E2006 25.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006 25.0 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each).
Study: NCT01463098
Drug: E2006 50.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006 50.0 mg capsule.
Study: NCT01463098
Drug: E2006 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006 100 mg (2 capsules of 50 mg each).
Study: NCT01463098
Drug: E2006 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006 200 mg (4 capsules of 50 mg each).
Study: NCT01463098
Drug: E2006 Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2006-matched placebo capsule.
Study: NCT01705574
Drug: E/C/F/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/300 mg FDC tablet administered orally with food once daily
Study: NCT00495651
Drug: Antiretroviral medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
Study: NCT00495651
Drug: Antiretroviral medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early ART initiation on the day of inclusion, before reaching the current WHO criteria
Study: NCT01705574
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tablet administered orally with food once daily
Study: NCT01705574
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/300 mg tablet administered orally with food once daily
Study: NCT01705574
Drug: E/C/F/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally with food once daily
Study: NCT01705574
Drug: ATV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally with food once daily
Study: NCT01705574
Drug: RTV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered orally with food once daily
Study: NCT01705574
Drug: FTC/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally with food once daily
Study: NCT01705574
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablet administered orally with food once daily
Study: NCT01405456
Drug: Eplerenone and lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: eplerenone 50mg by mouth daily as well as lifestyle counseling
Study: NCT00731172
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous daiky injection through week 12
Study: NCT00859521
Drug: Keppra®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Tablet
Study: NCT02914262
Drug: AKB-4924
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of different dosages of AKB-4924
Study: NCT01934088
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006023
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00834132
Drug: Azithromycin 600 mg Tablet
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 x 600mg, single-dose fed
Study: NCT00834132
Drug: Zithromax® 600 mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 600mg, single-dose fed
Study: NCT03558854
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
Study: NCT03558854
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
Study: NCT02840097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is provided to participants if randomized to this treatment arm.
Study: NCT00164775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tab nocte for first 2 weeks then 2 tabs for 10 weeks
Study: NCT03754309
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT00666627
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once monthly
Study: NCT00430508
Drug: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
Study: NCT00430508
Drug: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
Study: NCT00430508
Drug: olmesartan medoxomil/hydrochlorothiazide tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
Study: NCT00430508
Drug: olmesartan medoxomil/hydrochlorothiazide tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
Study: NCT01637233
Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors
Normalized name: Nucleoside and nucleotide reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI+PI
Study: NCT04673162
Drug: Methylprednisolone, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv administration
Study: NCT01147939
Drug: Investigator's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
Study: NCT00797823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution 0.9%
Study: NCT00810979
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were dosed with the statin prescribed specifically by their prescribing physician.
Study: NCT00003211
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01882491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection